Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)

Mild Cognitive Impairment (MCI) Clinical Trial

— ADNI3  

Official title:

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02854033
• Other study ID #: ATRI-001
• Secondary ID: U01AG024904
• Status: Recruiting
• Start date: October 2016
• Est. completion date: July 2024

Study information

• Verified date: April 2024
• Source: University of Southern California
• Contact: ADNI Study Central Phone Number
• Phone: (213) 821-0569
• Email: adni-participate[@]usc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

Description:

The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. This is multi-center, a non-randomized, natural history, non-treatment study. 1,070-2,000 total participants will be enrolled across three cohorts: cognitively normal* (CN), mild cognitive impairment (MCI) and mild Alzheimer's Disease (AD) dementia. Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts. Participants will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years. *currently recruiting non-Caucasian participants only for the cognitively normal cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 90 Years

Eligibility

Inclusion Criteria (all CN participants):

1. Participant with or without subjective memory complaints, verified by a study partner, beyond what one would expect for age

2. Normal memory function documented by scoring above education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the

Wechsler Memory Scale -Revised (the maximum score is 25):

1. 9 for 16 or more years of education

2. 5 for 8-15 years of education

3. 3 for 0-7 years of education

3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)

4. Clinical Dementia Rating = 0. Memory Box score must be 0

5. Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living

6. Stability of Permitted Medications for at least 4 weeks:

1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)

2. Estrogen replacement therapy is permissible

3. Gingko biloba is permissible, but discouraged

4. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria (all MCI participants):

1. Participant must express a subjective memory concern as reported by participant, or recalled by study partner or clinician.

2. Abnormal memory function documented by scoring below education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale -Revised (the maximum score is 25): a. < 11 for 16 or more years of education b. = 9 for 8-15 years of education c. = 6 for 0-7 years of education

3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)

4. Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5

5. General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the Screening Visit

6. Stability of Permitted Medications for at least 4 weeks:

1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)

2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to Screening Visit

3. Estrogen replacement therapy is permissible

4. Gingko biloba is permissible, but discouraged

5. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria (all AD participants):

1. Participant must express a subjective memory concern as reported by participant, or recalled by study partner or clinician.n.

2. Abnormal memory function documented by scoring below education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the

Wechsler Memory Scale -Revised (the maximum score is 25):

1. = 8 for 16 or more years of education

2. = 4 for 8-15 years of education

3. = 2 for 0-7 years of education

3. Mini-Mental State Exam score between 20 and 26 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)

4. Clinical Dementia Rating = 0.5 or 1.0

5. NINCDS (National Institute of Neurological and Communicative Disorders and Stroke) -ADRDA (Alzheimer's Disease and Related Disorders Association) criteria for probable AD

6. Stability of Permitted Medications for at least 4 weeks:

1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)

2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to Screening Visit

3. Estrogen replacement therapy is permissible

4. Gingko biloba is permissible, but discouraged

5. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening. Inclusion Criteria Specific to Newly Enrolled Participants

1. Geriatric Depression Scale score less than 6.

2. Age between 55-90 years (inclusive).

3. Study partner who has frequent contact with the participant (i.e., minimum average of 10 hours per week) and is available to accompany the participant to all clinic visits for the duration of the protocol.

4. Visual and auditory acuity adequate for neuropsychological testing.

5. Good general health with no diseases expected to interfere with the study.

6. Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).

7. Willing and able to participate in a longitudinal imaging study.

8. Modified Hachinski Ischemic Score less than or equal to 4.

9. Completed six grades of education or has a good work history (sufficient to exclude mental retardation).

10. Must speak English or Spanish fluently.

11. Willing to undergo repeated MRIs (3Tesla) and at least two PET scans

12. Agrees to collection of blood for genomic analysis (including GWAS (genome-wide association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and biospecimen banking.

13. Agrees to collection of blood for biomarker testing.

14. Agrees to at least one lumbar puncture for the collection of CSF.

15. Agrees to share genomic data and biomarker samples. Inclusion Criteria Specific to Rollover Participants" The following additional inclusion criteria apply to all diagnostic categories for rollover

participants only:

1. Must have been enrolled and followed in ADNI-1, ADNI-GO, or ADNI-2 for at least one year.

2. Willing and able to continue to participate in an ongoing longitudinal study. A reduced battery of tests is allowable if the participant is not able/willing to complete the full battery.

Exclusion Criteria (all CN participants):

1. Any significant neurologic disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities

Exclusion Criteria (all MCI participants):

1. Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.

Exclusion Criteria (all AD participants):

1. Any significant neurologic disease other than Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities. Exclusion Criteria (all participants):

The following additional exclusion criteria apply to all diagnostic categories:

1. Screening/Baseline MRI brain scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure

2. Subjects that have any contraindications for MRI studies, including the presence of cardiac pacemakers, or metal fragments or foreign objects in the eyes, skin or body.

3. Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol.

4. Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder.

5. History of schizophrenia (DSM IV criteria).

6. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).

7. Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol.

8. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.

9. Residence in a skilled nursing facility.

10. Current use of specific psychoactive medications (e.g., certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics). Current use of warfarin or other anticoagulants such as dabigatran, rivaroxaban and apixaban (exclusionary for lumbar puncture).

11. Current use of any other exclusionary medications

12. Investigational agents are prohibited one month prior to entry and for the duration of the trial.

13. Participation in clinical studies involving neuropsychological measures being collected more than one time per year. Exclusion Criteria Specific to AV-1451 PET:

The following criteria are exclusionary only for the AV-1451 scanning portion of the study:

1. History of risk factors for torsades de pointes (a cardiac dysrhythmia associated with sudden death) or taking medications known to prolong the QT interval. A list of restricted medications will be provided.

2. Have an ECG obtained prior to the AV-1451 PET scan that in the opinion of the investigator is clinically significant with regard to the subject's participation in the study. Bazett's corrected QT (QTcB) interval must be evaluated and must not exceed 458 msec in males, or 474 msec in females.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease (AD)
• Cognitive Dysfunction
• Mild Cognitive Impairment (MCI)

Locations

Country	Name	City	State
Canada	Parkwood Institute	London	Ontario
Canada	St. Joseph's Health Center - Cognitive Neurology	London	Ontario
Canada	Jewish General Hospital Memory Clinic	Montreal	Quebec
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	University of British Columbia, Clinic for AD & Related	Vancouver	British Columbia
United States	Albany Medical College	Albany	New York
United States	University of Michigan, Ann Arbor	Ann Arbor	Michigan
United States	Emory University	Atlanta	Georgia
United States	Johns Hopkins University	Baltimore	Maryland
United States	Case Western Reserve University	Beachwood	Ohio
United States	University of Alabama, Birmingham	Birmingham	Alabama
United States	Boston University School of Medicine	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dent Neurologic Institute	Buffalo	New York
United States	Ralph H. Johnson VA Health Care System	Charleston	South Carolina
United States	Northwestern University	Chicago	Illinois
United States	Rush University Medical Center	Chicago	Illinois
United States	Ohio State University	Columbus	Ohio
United States	University of Texas, Southwestern MC at Dallas	Dallas	Texas
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Kansas	Fairway	Kansas
United States	Baylor College of Medicine	Houston	Texas
United States	Houston Methodist	Houston	Texas
United States	Indiana University	Indianapolis	Indiana
United States	University of Iowa	Iowa City	Iowa
United States	University of California, Irvine	Irvine	California
United States	Mayo Clinic, Jacksonville	Jacksonville	Florida
United States	University of California, San Diego	La Jolla	California
United States	Cleveland Clinic Lou Ruvo Center for Brain Health	Las Vegas	Nevada
United States	University of Kentucky	Lexington	Kentucky
United States	Long Beach VA Neuropsychiatric Research Program	Long Beach	California
United States	University of California, Los Angeles	Los Angeles	California
United States	University of Southern California	Los Angeles	California
United States	University of Wisconsin	Madison	Wisconsin
United States	Wien Center for Clinical Research	Miami Beach	Florida
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale University School of Medicine	New Haven	Connecticut
United States	Columbia University	New York	New York
United States	Mount Sinai School of Medicine	New York	New York
United States	New York University Medical Center	New York	New York
United States	Nathan Kline Institute for Psychiatric Research	Orangeburg	New York
United States	VA Palo Alto HSC / Stanford School of Medicine	Palo Alto	California
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Banner Alzheimer's Institute	Phoenix	Arizona
United States	Barrow Neurological Institute	Phoenix	Arizona
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Oregon Health & Science University	Portland	Oregon
United States	Butler Hospital Memory and Aging Program	Providence	Rhode Island
United States	Rhode Island Hospital	Providence	Rhode Island
United States	Mayo Clinic, Rochester	Rochester	Minnesota
United States	University of Rochester	Rochester	New York
United States	Washington University, St. Louis	Saint Louis	Missouri
United States	University of California, San Francisco	San Francisco	California
United States	Banner Sun Health Research Institute	Sun City	Arizona
United States	University of South Florida - Health Byrd Alzheimer Institute	Tampa	Florida
United States	University of California, Davis	Walnut Creek	California
United States	Georgetown University	Washington	District of Columbia
United States	Howard University	Washington	District of Columbia
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (4)

Lead Sponsor	Collaborator
University of Southern California	Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Northern California Institute of Research and Education

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)	The ADAS-Cog is an in-person examiner-administered, structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained.	5 years
Primary	Rate of change in cognition as measured by the Logical Memory Test I and II		5 years
Primary	Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)	The MMSE scale evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons.	5 years
Secondary	Rate of change in cognition as measured by the Cogstate Brief Battery (CBB)	The Cogstate Brief battery (CBB) is a brief (10-15 minute) computerized cognitive battery developed by Cogstate (Cogstate Ltd. New Haven, CT, USA) that measures attention, speed of information processing, working memory and learning.	5 years
Secondary	Rate of change in cognition as measured by the American National Adult Reading Test (ANART)	The ANART estimates premorbid verbal intelligence (VIQ) in patients with dementia.	5 years
Secondary	Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)	The Montreal Cognitive Assessment test (MoCA) is a cognitive assessment designed to detect participants at the MCI stage of cognitive dysfunction.	5 years
Secondary	Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test	The AVLT is a list-learning task, which assesses multiple cognitive parameters associated with learning and memory.	5 years
Secondary	Rate of change in cognition as measured by the Trail Making Test: A and B		5 years
Secondary	Change in tau deposition as measured by 18F-AV-1451		5 years
Secondary	Change in amyloid deposition as measured by Florbetapir		5 years
Secondary	Change in amyloid deposition as measured by Florbetaben		5 years
Secondary	Rate of conversion to MCI or dementia due to AD		5 years
Secondary	Rates of change of glucose metabolism (FDG-PET)		5 years
Secondary	Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers		5 years
Secondary	Change in brain structure using magnetic resonance imaging (MRI)		5 years

External Links

•   Alzheimer's Disease Neuroimaging Initiative
•   Alzheimer's Therapeutic Research Institute
•   Brain Health Registry (BHR)
•   Laboratory of Neuro Imaging (LONI)
•   List of Alzheimer's Disease Neuroimaging Initiative Publications